AMAli Mehdi

Ali Mehdi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Mehdi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thrombotic Microangiopathy And Hypertensive Emergency After Cocaine Use: A Case Report

    by José Manuel Moreno-Mirón, Juan de Dios Alfonso, Tyler White, Ali Mehdi, Moises Auron

    A patient in her early 60s presented with hypertensive emergency, microangiopathic hemolytic anemia, thrombocytopenia, and non-oliguric acute kidney injury (AKI) after recent cocaine use. The evaluation demonstrated schistocytes, a Coombs-negative hemolysis pattern, and preserved ADAMTS13 activity, making TTP unlikely. Kidney biopsy confirmed acute thrombotic microangiopathy (TMA) and excluded alternative intrinsic renal pathologies. Autoimmune and infectious workup was unrevealing. Although cocaine exposure temporally preceded presentation, malignant hypertension and complement activation may represent overlapping and potentially synergistic mechanisms rather than a single unifying etiology. Blood pressure control improved hemodynamics, but kidney function continued to worsen, and soluble C5b-9 (sC5b-9) was elevated. Eculizumab was initiated empirically after appropriate vaccination due to persistent renal dysfunction despite blood pressure optimization, recognizing that sC5b-9 is not specific for atypical HUS and may be elevated in secondary TMAs. Renal function subsequently stabilized, and the patient remained dialysis-free at three-month follow-up.

  • Open Access

    Immunotactoid hepatopathy: A novel entity with histologically proven recurrence post liver transplantation

    by Ahmed Bakhshwin, Leal Herlitz, Shaomin Hu, Shahzad Raza, Dane C. Olevian, Ali Mehdi, Kenneth Friedman, Bijan Eghtesad, Koji Hashimoto, Jamak Modaresi Esfeh, et al.

  • Open Access

    Treatment and practical considerations of diabetic kidney disease

    by Yara Bilen, Allaa Almoushref, Kenda Alkwatli, Omar Osman, Ali Mehdi, Hanny Sawaf

    Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease. In the early 90s, angiotensin blockade (ACEi and ARBs) was introduced, which revolutionized the treatment of DKD. In recent years, newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin antagonists, and mineralocorticoid receptor antagonists (MRA) have shown great promise in reducing albuminuria and protecting the kidneys. These drugs are being used in combination with lifestyle modifications, patient education, and risk factor modification to effectively manage DKD. In this review, we will explore the latest pharmacological options, their efficacy, and their potential to revolutionize the management of this debilitating disease.


  • Impact of the COVID-19 Pandemic on Nephrology Fellow Training and Well-Being in the United States: A National Survey

    by Kurtis A. Pivert, Suzanne M. Boyle, Susan M. Halbach, Lili Chan, Hitesh H. Shah, Joshua S. Waitzman, Ali Mehdi, Sayna Norouzi, Stephen M. Sozio

    Aims: Mutation of the KRAS gene predicts the clinical response to the monoclonal antibody cetuximab in patients with advanced colorectal cancer (CRC). This study aimed to perform KRAS mutation detection on formalin-fixed paraffin-embedded (FFPE) tumour tissue by two different methods for comparison. Methods: The FFPE sample was microdissected to enrich for tumour cells. KRAS exon 2 mutations were performed on 100 Chinese patients with CRC by direct nucleotide sequencing and high-resolution melting (HRM) analysis. Results: KRAS exon 2 mutations were detected in a total of 62 patients with the two methods combined, comprising 11 different mutant alleles. Three common mutations p.Gly12Asp, p.Gly12Val and p.Gly13Asp accounted for approximately 70% of all cases. The concordant rate between the two methods was 95%. Four mutations not initially detected by direct sequencing were identified by HRM and confirmed by sequencing of the HRM amplicons. One mutation detected by direct sequencing was inadvertently grouped as a wild-type allele by HRM software, but this was readily rectified through manual review. Conclusion: HRM analysis is a sensitive method of detecting KRAS mutation on FFPE tumour tissue to guide cetuximab treatment and is applicable to routine molecular diagnostic service. Utilisation of HRM to screen for mutations upfront economises the resource used in the sequencing reaction.


  • 2019 Nephrology Fellow Survey Results And Insights

    by Stephen M. Sozio, Kurtis A. Pivert, Suzanne M. Boyle, Lili Chan, Kelsea McDyre, Ali Mehdi, Sayna Norouzi, Shamir Tuchman, Joshua Waitzman

    Women Fellow Respondents Report More Debt, Lower Starting Salaries in 2019